Clinicopathological features and prognostic significance of HER2 expression in gastric cancer.

IF 1.8 3区医学 Q3 ONCOLOGY Oncology Pub Date : 2015-01-01 Epub Date: 2014-11-13 DOI:10.1159/000368555

Ji Soo Park, Sun Young Rha, Hyun Cheol Chung, Minkyu Jung, Ki Hyang Kim, Hyun Jung Jun, Hyunki Kim, Ji Yeong An, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyo Song Kim

{"title":"Clinicopathological features and prognostic significance of HER2 expression in gastric cancer.","authors":"Ji Soo Park, Sun Young Rha, Hyun Cheol Chung, Minkyu Jung, Ki Hyang Kim, Hyun Jung Jun, Hyunki Kim, Ji Yeong An, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyo Song Kim","doi":"10.1159/000368555","DOIUrl":null,"url":null,"abstract":"Background: HER2 positivity is reported to be <20% in gastric cancer. Clinicopathological characteristics will be helpful to understand the biological features of HER2-positive gastric cancer.Methods: A total of 813 gastric cancer patients who underwent HER2 testing between January 2005 and December 2010 were included in this study.Results: Ninety-five (11.7%) patients had HER2-positive gastric cancer. Elevated serum carcinoembryonic antigen (CEA) concentration [odds ratio (OR), 5.629; p < 0.001] and differentiated histology (OR, 3.717; p = 0.002) were significant predictive factors for HER2 positivity in localized disease. For recurrent or metastatic disease, elevated serum CEA concentration (OR, 2.545; p < 0.001), differentiated histology (OR, 3.299; p < 0.001), pulmonary metastasis (OR, 3.321; p = 0.001), and distant lymph node metastasis (OR, 2.286; p = 0.002) were significant predictive factors. Median disease-free survival (DFS) was shorter in HER2-positive patients than in others, especially in stage I or II disease (24.7 vs. 49.2 months; p < 0.001). Among HER2-negative patients with stage II diseases, patients who received adjuvant chemotherapy had longer DFS than others (42.2 vs. 30.7 months; p = 0.025).Conclusions: Clinicopathological factors may be useful in predicting the HER2 positivity of gastric cancer. Further studies are needed to understand the molecular basis of HER2-positive gastric cancer.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":"88 3","pages":"147-56"},"PeriodicalIF":1.8000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000368555","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000368555","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/11/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 14

Abstract

Background: HER2 positivity is reported to be <20% in gastric cancer. Clinicopathological characteristics will be helpful to understand the biological features of HER2-positive gastric cancer.

Methods: A total of 813 gastric cancer patients who underwent HER2 testing between January 2005 and December 2010 were included in this study.

Results: Ninety-five (11.7%) patients had HER2-positive gastric cancer. Elevated serum carcinoembryonic antigen (CEA) concentration [odds ratio (OR), 5.629; p < 0.001] and differentiated histology (OR, 3.717; p = 0.002) were significant predictive factors for HER2 positivity in localized disease. For recurrent or metastatic disease, elevated serum CEA concentration (OR, 2.545; p < 0.001), differentiated histology (OR, 3.299; p < 0.001), pulmonary metastasis (OR, 3.321; p = 0.001), and distant lymph node metastasis (OR, 2.286; p = 0.002) were significant predictive factors. Median disease-free survival (DFS) was shorter in HER2-positive patients than in others, especially in stage I or II disease (24.7 vs. 49.2 months; p < 0.001). Among HER2-negative patients with stage II diseases, patients who received adjuvant chemotherapy had longer DFS than others (42.2 vs. 30.7 months; p = 0.025).

Conclusions: Clinicopathological factors may be useful in predicting the HER2 positivity of gastric cancer. Further studies are needed to understand the molecular basis of HER2-positive gastric cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胃癌中HER2表达的临床病理特征及预后意义。

方法:2005年1月至2010年12月期间接受HER2检测的813例胃癌患者纳入本研究。结果:95例(11.7%)患者为her2阳性胃癌。血清癌胚抗原(CEA)浓度升高[优势比(OR)， 5.629;p < 0.001]和分化组织学(OR, 3.717;p = 0.002)是局限性疾病中HER2阳性的重要预测因素。对于复发或转移性疾病，血清CEA浓度升高(or, 2.545;p < 0.001)，分化组织学(OR, 3.299;p < 0.001)，肺转移(OR, 3.321;p = 0.001)，远处淋巴结转移(OR, 2.286;P = 0.002)为显著的预测因素。her2阳性患者的中位无病生存期(DFS)短于其他患者，尤其是I期或II期患者(24.7个月vs 49.2个月;P < 0.001)。在her2阴性的II期疾病患者中，接受辅助化疗的患者的DFS比其他患者更长(42.2个月vs 30.7个月;P = 0.025)。结论:临床病理因素可能是预测胃癌HER2阳性的重要因素。需要进一步的研究来了解her2阳性胃癌的分子基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.